Literature DB >> 17852716

Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy.

A Schilling1, M Seibold, V Mansmann, B Gleissner.   

Abstract

Candidal vertebral osteomyelitis represents an extremely rare invasive mycosis and can be difficult to treat due to poor drug penetration into bony tissue. We report on a case of vertebral osteomyelitis caused by Candida krusei in a patient who had neutropenia as a result of chemotherapy for acute myelogenous leukaemia. The patient received prophylactic liposomal amphotericin B during chemotherapy but became febrile and experienced severe lumbar pain. Magnetic resonance imaging revealed vertebral osteochondrosis. C. krusei was recovered from blood cultures and voriconazole monotherapy was initiated but proved unsuccessful. The patient was then started on caspofungin monotherapy, which was discontinued after Candida krusei was no longer recoverable from blood cultures. However, as lumbar pain increased and spinal biopsy confirmed the presence of Candida krusei, caspofungin therapy was resumed. Oral posaconazole was added to the regimen when the patient did not improve after 30 days of caspofungin therapy. Combined antimycotic therapy resulted in a successful outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17852716     DOI: 10.1080/13693780701552996

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  8 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Successful treatment of azole-resistant Candida spondylodiscitis with high-dose caspofungin monotherapy.

Authors:  Theodoros Kelesidis; Kelesidis Theodoros; Sotirios Tsiodras; Tsiodras Sotirios
Journal:  Rheumatol Int       Date:  2011-09-03       Impact factor: 2.631

Review 4.  Talus osteomyelitis by Candida krusei with multiple huge cystic lesions: a case report and review of literatures.

Authors:  Hyungtae Kim; Su-Young Bae
Journal:  BMC Musculoskelet Disord       Date:  2022-07-19       Impact factor: 2.562

5.  Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011).

Authors:  Maria N Gamaletsou; Dimitrios P Kontoyiannis; Nikolaos V Sipsas; Brad Moriyama; Elizabeth Alexander; Emmanuel Roilides; Barry Brause; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-08-21       Impact factor: 9.079

6.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

7.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

Review 8.  An Italian consensus for invasive candidiasis management (ITALIC).

Authors:  L Scudeller; C Viscoli; F Menichetti; V del Bono; F Cristini; C Tascini; M Bassetti; P Viale
Journal:  Infection       Date:  2013-11-25       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.